NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
P |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
Metastatic Breast Cancer|HER2 Positive Breast Carcinoma |
Drug: Niraparib|Drug: Trastuzumab |
University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Tesaro, Inc.|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation of Alabama |
1
2 |
NCT03368859 |
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab |
Cancer - Metastatic Colorectal |
Drug: ABT-165|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Fluorouracil - bolus|Drug: Fluorouracil - infusion |
AbbVie |
2 |
NCT03367871 |
Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer |
Cervical Cancer |
Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Cisplatin |
University of Miami |
2 |
NCT03367754 |
A Single Dose of Pembrolizumab in HIV-Infected People |
Human Immunodeficiency Virus |
Other: Placebo|Drug: Pembrolizumab |
National Institutes of Health Clinical Center (CC) |
1 |
NCT03367715 |
A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma |
MGMT-unmethylated Glioblastoma (GBM)|GBM |
Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy (RT) |
New York University School of Medicine |
2 |
NCT03366766 |
Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery |
Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer AJCC v7|Stage IA Non-Small Cell Lung Carcinoma AJCC v7|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7 |
Biological: Nivolumab|Drug: Cisplatin|Drug: Pemetrexed Disodium|Drug: Gemcitabine Hydrochloride |
Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University |
2 |
NCT03366155 |
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver |
Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma |
Drug: Floxuridine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Irinotecan|Drug: Panitumumab |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2 |
NCT03366142 |
Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology |
Leukocyte Adhesion Deficiency Type 1 |
Biological: Ustekinumab |
National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
2 |
NCT03365882 |
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery |
Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7 |
Biological: Cetuximab|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pertuzumab|Biological: Trastuzumab|Device: HER-2 testing |
Southwest Oncology Group|National Cancer Institute (NCI) |
2 |
NCT03365661 |
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML |
High-Risk Acute Myeloid Leukemia|Treatment-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Myelodysplastic Syndrome |
Biological: ALT-803 |
Masonic Cancer Center, University of Minnesota|University of Minnesota - Clinical and Translational Science Institute |
2 |
NCT03364348 |
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer |
HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
Drug: Utomilumab|Drug: Trastuzumab|Drug: Trastuzumab Emtansine |
George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University |
1 |
NCT03361852 |
A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma |
Follicular Lymphoma |
Drug: Rituximab|Biological: Neo Vax |
Dana-Farber Cancer Institute |
1 |
NCT03361748 |
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) |
Multiple Myeloma |
Biological: bb2121 |
Celgene |
2 |
NCT03369223 |
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread |
Advanced Cancer |
Biological: BMS-986249|Biological: Nivolumab |
Bristol-Myers Squibb |
1
2 |
NCT03362060 |
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer |
Triple Negative Breast Cancer|Metastatic Breast Cancer |
Drug: Pembrolizumab|Biological: PVX-410 |
Massachusetts General Hospital|Merck Sharp & Dohme Corp. |
1 |
NCT03367377 |
A Study of LY3209590 in Participants With Type 2 Diabetes |
Diabetes Mellitus, Type 2 |
Drug: LY3209590|Drug: Insulin Glargine |
Eli Lilly and Company |
1 |
NCT03363373 |
Naxitamab for Neuroblastoma With Osteomedullary Disease |
Neuroblastoma |
Biological: GM-CSF + hu3F8 |
Y-mAbs Therapeutics |
3 |